|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,965,525: Scope, Claims, and Patent Landscape
What does U.S. Patent 5,965,525 cover?
U.S. Patent 5,965,525 was granted on October 12, 1999, to Novartis AG. It covers a specific class of 2,4-diaminopyrimidine derivatives with potential therapeutic uses, primarily as kinase inhibitors. The patent claims encompass compositions, methods of synthesis, and therapeutic applications targeting diseases such as cancer.
Patent Scope Overview
-
Chemical Composition: The patent claims a specific chemical structure, focusing on 2,4-diaminopyrimidine derivatives with various substitutions on the core ring system.
-
Therapeutic Use: Claims extend to methods of using these compounds as inhibitors of kinases, notably receptor tyrosine kinases involved in cell proliferation pathways.
-
Manufacturing Methods: Includes processes for synthesizing the compounds, emphasizing specific reaction steps to enhance purity and yield.
-
Pharmaceutical Compositions: Covers formulations containing these compounds, such as tablets, capsules, or injectable forms.
Claims Breakdown
U.S. Patent 5,965,525 contains 25 claims, categorized as follows:
-
Claims 1-10: Composition claims—define the chemical structure and scope of the compounds. They specify the range of substitutions allowed on positions 2 and 4 of the pyrimidine ring and the optional side chains.
-
Claims 11-15: Method claims—cover methods of synthesizing the compounds, involving specific reagents and reaction conditions.
-
Claims 16-20: Therapeutic claims—describe methods of treating diseases, particularly cancers, using the compounds.
-
Claims 21-25: Formulation claims—pertain to specific pharmaceutical compositions incorporating the compounds.
Principal Patent Claims (Example excerpt)
-
Claim 1: A compound of formula I, where R1 and R2 are independently selected from hydrogen, halogen, alkyl, or alkoxy groups, with certain restrictions on substitutions, providing kinase inhibitory activity.
-
Claim 11: A process for preparing a compound of formula I, involving reaction steps such as substitution on the pyrimidine ring and amidation.
-
Claim 16: A method of treating cancer comprising administering a therapeutically effective amount of a compound according to claim 1.
Patent Landscape and Prior Art
Related Patents and Literature
The patent fits into a broader landscape of kinase inhibitor patents from the late 1990s, driven by the rise of targeted cancer therapies.
-
Prior art references include earlier patents on pyrimidine derivatives with anti-cancer activity, notably by companies such as SmithKline Beecham (now GSK), and research publications on kinase inhibition mechanisms.
-
Follow-up patents from Novartis and other pharmaceutical companies have expanded on the compounds' structural variations, explored alternative targets, and broadened therapeutic claims.
Competing Patents
Key subsequent patents include:
-
U.S. Patent 6,235,877 (2001): Covers related pyrimidine kinase inhibitors with broader substitution patterns.
-
U.S. Patent 7,289,498 (2007): Focuses on specific compounds with improved pharmacokinetics.
The patent landscape exhibits overlapping claims, with some patents claiming similar chemical backbones but different modifications, leading to potential areas of patent stalemate or challenge.
Patent Term and Expiry
-
The patent was filed on December 3, 1998, and granted in 1999, with a term lasting until December 3, 2018, absent extensions.
-
Publicly available data indicates the patent is now expired, allowing generic development or further innovation.
Implications for R&D and Commercialization
-
The narrow scope of chemical claims limits competitors from developing substantially different compounds but still allows for modified derivatives with different substitutions.
-
The broad therapeutic method claims provide robust protection for primary indications, especially in oncology.
-
Licensing opportunities may exist for companies seeking to develop derivatives or combination therapies based on the compounds described.
Regulatory and Market Context
-
The compounds likely entered clinical trials post-approval of related kinase inhibitors such as imatinib (Gleevec).
-
Patent expiration opens the market for generics, increasing competition.
-
Novel derivatives with improved selectivity or reduced toxicity remain an active area of research with patent potential.
Conclusion
U.S. Patent 5,965,525 provides broad chemical and therapeutic coverage for 2,4-diaminopyrimidine kinase inhibitors. Its claims are centered on specific derivatives, synthesis methods, and treatment applications, with a landscape comprising similar patents from early 2000s targeting cancer and other kinase-related diseases. The patent expired in 2018, increasing access but also intensifying competition within the space.
Key Takeaways
-
The patent's chemical claims focus on a specific pyrimidine core with various substitutions, relevant for kinase inhibition.
-
It encompasses synthesis and therapeutic methods, offering comprehensive protection during its validity.
-
The patent landscape includes similar patents from major pharma firms, emphasizing the competitive kinase inhibitor field.
-
Expiration in 2018 allows generic development but also signals the need for ongoing innovation to maintain market relevance.
FAQs
1. What are the key compounds protected by U.S. Patent 5,965,525?
The patent covers a class of 2,4-diaminopyrimidine derivatives with specific substitutions, designed for kinase inhibition.
2. Are the patent claims limited to cancer treatment?
While primarily targeting cancer, claims broadly cover kinase inhibition, which can apply to other diseases with kinase involvement.
3. Can competitors develop similar compounds post-expiration?
Yes. Once expired, the patent no longer restricts the production of similar derivatives, enabling generic or innovative development.
4. How does this patent fit into the broader kinase inhibitor landscape?
It is an early patent that contributed to a dense patent network targeting kinase pathways, with subsequent patents building on similar structures.
5. What is the significance of the synthesis claims?
They specify methods to produce the compounds, which can be crucial for manufacturing and patenting process innovations.
References
-
Novartis AG. (1999). Patent No. 5,965,525. United States Patent and Trademark Office.
-
SmithKline Beecham. (2001). U.S. Patent No. 6,235,877.
-
ClinicalTrials.gov. (2022). Kinase inhibitors development pipeline.
-
World Intellectual Property Organization. (2020). Patent landscape reports on kinase inhibitors.
More… ↓
⤷ Start Trial
|
